Literature DB >> 22778877

Patient selection and preparation strategies for the use of contrast material in patients with chronic kidney disease.

Poul Erik Andersen1.   

Abstract

The prevalence of chronic kidney disease and peripheral arterial disease is increasing. Thus, it is increasingly problematic to image these patients as the number of patients needing a vascular examination is increasing accordingly. In high-risk patients with impaired kidney function, intravascular administration of iodinated contrast media can result in contrast-induced acute kidney injury and Gadolinium can induce nephrogenic systemic fibrosis (NSF). It is important to identify these high-risk patients by means of se-creatinine/e glomerular filtration rate. The indication for contrast examination should counterbalance the increased risk. One or more alternative examination methods without contrast media, such as CO(2) angiography, Ultrasound/Doppler examination or magnetic resonance angiography without contrast should be considered, but at the same time, allow for a meaningful outcome of the examination. If contrast is deemed essential, the patient should be well hydrated, the amount of contrast should be restricted, the examination should be focused, metformin and diuretics stopped, and renal function monitored. Sodium bicarbonate and N-acetylcysteine are popular but their efficiency is not evidence-based. There is no evidence that dialysis protects patients with impaired renal function from contrast-induced nephropathy or NSF.

Entities:  

Keywords:  Arterial disease; Chronic; Diabetes complications; Diabetic; Interventional; Kidney failure; Nephropathies; Peripheral; Radiology; Renal insufficiency

Year:  2012        PMID: 22778877      PMCID: PMC3391670          DOI: 10.4329/wjr.v4.i6.253

Source DB:  PubMed          Journal:  World J Radiol        ISSN: 1949-8470


  17 in total

1.  Prevalence of advanced renal failure in Northern Ireland.

Authors:  M G McGeown
Journal:  BMJ       Date:  1990-10-20

2.  Nephrogenic systemic fibrosis and contrast medium-induced nephropathy: a choice between the devil and the deep blue sea for patients with reduced renal function?

Authors:  K Lind Ramskov; H S Thomsen
Journal:  Acta Radiol       Date:  2009-11       Impact factor: 1.990

3.  B-type natriuretic peptide for prevention of contrast-induced nephropathy in patients with heart failure undergoing primary percutaneous coronary intervention.

Authors:  Jing Zhang; Xianghua Fu; Xinwei Jia; Xinna Fan; Xinshun Gu; Shiqiang Li; Weili Wu; Weize Fan; Jianling Su; Guozhen Hao; Yunfa Jiang; Ling Xue
Journal:  Acta Radiol       Date:  2010-07       Impact factor: 1.990

4.  Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging.

Authors:  Peter Marckmann; Lone Skov; Kristian Rossen; Anders Dupont; Mette Brimnes Damholt; James Goya Heaf; Henrik S Thomsen
Journal:  J Am Soc Nephrol       Date:  2006-08-02       Impact factor: 10.121

5.  Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients.

Authors:  Hani H Abujudeh; Rathachai Kaewlai; Anna Kagan; Lori B Chibnik; Rosalynn M Nazarian; Whitney A High; Jonathan Kay
Journal:  Radiology       Date:  2009-08-25       Impact factor: 11.105

6.  Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000.

Authors:  Elizabeth Selvin; Thomas P Erlinger
Journal:  Circulation       Date:  2004-07-19       Impact factor: 29.690

7.  Prevalence of lower-extremity disease in the US adult population >=40 years of age with and without diabetes: 1999-2000 national health and nutrition examination survey.

Authors:  Edward W Gregg; Paul Sorlie; Ryne Paulose-Ram; Qiuping Gu; Mark S Eberhardt; Michael Wolz; Vicki Burt; Lester Curtin; Michael Engelgau; Linda Geiss
Journal:  Diabetes Care       Date:  2004-07       Impact factor: 19.112

8.  Gadolinium-associated nephrogenic systemic fibrosis.

Authors:  Jeffrey D Schlaudecker; Christopher R Bernheisel
Journal:  Am Fam Physician       Date:  2009-10-01       Impact factor: 3.292

Review 9.  Peripheral arterial disease in patients with diabetes.

Authors:  Steven P Marso; William R Hiatt
Journal:  J Am Coll Cardiol       Date:  2006-02-09       Impact factor: 24.094

Review 10.  Prevention of contrast-induced nephropathy: an overview.

Authors:  James H Ellis; Richard H Cohan
Journal:  Radiol Clin North Am       Date:  2009-09       Impact factor: 2.303

View more
  3 in total

1.  Proton magnetic resonance spectroscopy in the evaluation of patients with acute Charcot neuro-osteoarthropathy.

Authors:  Francesca Bolacchi; Luigi Uccioli; Salvatore Masala; Laura Giurato; Valeria Ruotolo; Marco Meloni; Eleonora Baffari; Elenia Cinelli; Marcello Cadioli; Ettore Squillaci; Giovanni Simonetti; Alberto Bergamini
Journal:  Eur Radiol       Date:  2013-06-11       Impact factor: 5.315

2.  Expression of the receptor activator of nuclear factor-kB ligand in peripheral blood mononuclear cells in patients with acute Charcot neuroarthropathy.

Authors:  Alberto Bergamini; Francesca Bolacchi; Caterina Delfina Pesce; Giada Veneziano; Luigi Uccioli; Valentina Girardi; Laura De Corato; Maria Teresa Mondillo; Ettore Squillaci
Journal:  Int J Med Sci       Date:  2016-10-20       Impact factor: 3.738

3.  Impact of continuation of metformin prior to elective coronary angiography on acute contrast nephropathy in patients with normal or mildly impaired renal functions.

Authors:  Veysel Oktay; İlknur Calpar Çıralı; Ümit Yaşar Sinan; Ahmet Yıldız; Murat Kazım Ersanlı
Journal:  Anatol J Cardiol       Date:  2017-10-31       Impact factor: 1.596

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.